Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2002 1
2003 1
2004 3
2005 2
2006 1
2007 1
2008 4
2009 2
2010 1
2011 3
2012 2
2013 4
2014 2
2015 1
2016 3
2017 1
2019 1
2020 1
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Slingluff CL Jr, et al. Among authors: chianese bullock ka. Adv Immunol. 2006;90:243-95. doi: 10.1016/S0065-2776(06)90007-8. Adv Immunol. 2006. PMID: 16730266 Review.
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, Myers P, Mahoney KE, Shabanowitz J, Buettner N, Hall EH, Haden K, Cobbold M, Hunt DF, Weiss G, Gaughan E, Slingluff CL Jr. Engelhard VH, et al. Among authors: chianese bullock ka. J Immunother Cancer. 2020 May;8(1):e000262. doi: 10.1136/jitc-2019-000262. J Immunother Cancer. 2020. PMID: 32385144 Free PMC article. Clinical Trial.
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Wages NA, Olson WC, Smith KT, Haden K, Dengel LT, Dickinson A, Reed C, Gaughan EM, Grosh WW, Kaur V, Varhegyi N, Smolkin M, Galeassi NV, Deacon D, Hall EH. Slingluff CL Jr, et al. Among authors: chianese bullock ka. J Immunother Cancer. 2021 Jan;9(1):e000934. doi: 10.1136/jitc-2020-000934. J Immunother Cancer. 2021. PMID: 33479025 Free PMC article. Clinical Trial.
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO, Petroni GR, Salerno EP, Lynch KT, Smolkin M, Woodson E, Chianese-Bullock KA, Olson WC, Deacon D, Patterson JW, Grosh WW, Slingluff CL. Meneveau MO, et al. Among authors: chianese bullock ka. J Immunother Cancer. 2021 May;9(5):e002214. doi: 10.1136/jitc-2020-002214. J Immunother Cancer. 2021. PMID: 34035112 Free PMC article. Clinical Trial.
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr. Melssen MM, et al. Among authors: chianese bullock ka. J Immunother Cancer. 2019 Jun 27;7(1):163. doi: 10.1186/s40425-019-0625-x. J Immunother Cancer. 2019. PMID: 31248461 Free PMC article. Clinical Trial.
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
Patel SP, Petroni GR, Roszik J, Olson WC, Wages NA, Chianese-Bullock KA, Smolkin M, Varhegyi N, Gaughan E, Smith KT, Haden K, Hall EH, Gnjatic S, Hwu P, Slingluff CL. Patel SP, et al. Among authors: chianese bullock ka. J Immunother Cancer. 2021 Aug;9(8):e003220. doi: 10.1136/jitc-2021-003220. J Immunother Cancer. 2021. PMID: 34413169 Free PMC article. Clinical Trial.
Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.
Lulu AM, Cummings KL, Jeffery ED, Myers PT, Underwood D, Lacy RM, Chianese-Bullock KA, Slingluff CL Jr, Modesitt SC, Engelhard VH. Lulu AM, et al. Among authors: chianese bullock ka. Cancer Immunol Res. 2021 Nov;9(11):1327-1341. doi: 10.1158/2326-6066.CIR-21-0111. Epub 2021 Aug 19. Cancer Immunol Res. 2021. PMID: 34413086
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr. Mauldin IS, et al. Among authors: chianese bullock ka. Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13. Cancer Immunol Immunother. 2016. PMID: 27522581 Free PMC article. Clinical Trial.
39 results